HHLA2 promotes hepatoma cell proliferation, migration, and invasion via SPP1/PI3K/AKT signaling pathway
Molecular Carcinogenesis · 2024
DOI: 10.1002/mc.23723 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Carcinogenesis, 2024. Verfasst von Junqi Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Cell Proliferation, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: The 345 Talent Project of Shengjing Hospital, Natural Science Foundation of Liaoning Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) stands as one of the most malignant tumors characterized by poor prognosis and high mortality rates. Emerging evidence underscores the crucial role of the B7 protein family in various cancers, including HCC. However, the involvement of the human endogenous retrovirus H long‐terminal repeat‐associated protein 2 (HHLA2, or B7‐H5) in HCC remains unclear. Immunohistochemistry was employed to assess the differential expression of HHLA2 between HCC and normal liver tissues. A battery of assays, including CCK8, EdU, tablet clone‐forming, Transwell, and wound healing assays, were conducted to elucidate the function and potential mechanisms of HHLA2 in the malignant biological behaviors of HCC. Additionally, a xenograft mouse model was established to evaluate the tumorigenicity of hepatoma cell lines exhibiting different HHLA2 expression levels in vivo. Western blot analysis was used to analyze HHLA2, secretory phosphoprotein 1 (SPP1), and PI3K/AKT/mTOR levels. HHLA2 exhibited elevated expression in HCC tissues, correlating with poor tumor differentiation and shortened overall survival in HCC patients. In vitro experiments demonstrated that HHLA2 overexpression (OE) promoted the proliferation, migration, and invasion of hepatoma cells, while in vivo experiments revealed that HHLA2 OE enhanced HCC tumor growth. Conversely, inhibition of HHLA2 expression yielded the opposite effect. Downregulation of SPP1 inhibited the proliferation, migration, and invasion induced by HHLA2 OE, and this effect was linked to the PI3K/AKT/mTOR signaling pathway. Our findings indicate that HHLA2 promotes the proliferation, migration, and invasion of hepatoma cells via the SPP1/PI3K/AKT signaling pathway, establishing it as a potential therapeutic target for HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
- Department of Tradition Chinese Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Förderung
- The 345 Talent Project of Shengjing Hospital
- Natural Science Foundation of Liaoning Province
- National Natural Science Foundation of China
Zitieren
APA
Wang, J., Yang, K., Yang, X., Jin, T., Tian, Y., Dai, C., & Xu, F. (2024). HHLA2 promotes hepatoma cell proliferation, migration, and invasion via SPP1/PI3K/AKT signaling pathway. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23723
Vancouver
Wang J, Yang K, Yang X, Jin T, Tian Y, Dai C, et al. HHLA2 promotes hepatoma cell proliferation, migration, and invasion via SPP1/PI3K/AKT signaling pathway. Molecular Carcinogenesis. 2024. doi:10.1002/mc.23723
BibTeX
@article{Wang2024,
author = {Wang, Junqi and Yang, Ke and Yang, Xin and Jin, Tianqiang and Tian, Yu and Dai, Chaoliu and Xu, Feng},
title = {HHLA2 promotes hepatoma cell proliferation, migration, and invasion via SPP1/PI3K/AKT signaling pathway},
journal = {Molecular Carcinogenesis},
year = {2024},
doi = {10.1002/mc.23723}
}
EUVIMED